Abstract
Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn’s disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.
Keywords: Primary immunodeficiency diseases, anti-inflammatory drugs, inflammation, autoimmunity, chronic inflammatory diseases, regulatory T cells, immune tolerance
Current Pharmaceutical Design
Title:Defective and Excessive Immunities in Pediatric Diseases
Volume: 18 Issue: 35
Author(s): Luigi Daniele Notarangelo and Alberto Tommasini
Affiliation:
Keywords: Primary immunodeficiency diseases, anti-inflammatory drugs, inflammation, autoimmunity, chronic inflammatory diseases, regulatory T cells, immune tolerance
Abstract: Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn’s disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.
Export Options
About this article
Cite this article as:
Daniele Notarangelo Luigi and Tommasini Alberto, Defective and Excessive Immunities in Pediatric Diseases, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530943
DOI https://dx.doi.org/10.2174/138161212803530943 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Targeting Post-Ejaculation Sperm for Value-Added Contraception
Current Molecular Pharmacology Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Development of Novel miRNA-based Vaccines and Antivirals against Enterovirus 71
Current Pharmaceutical Design The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Dysfunctional Adaptive Immunity During Parasitic Infections
Current Immunology Reviews (Discontinued) Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Novel and Viable Acetylcholinesterase Target Site for Developing Effective and Environmentally Safe Insecticides
Current Drug Targets HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Ocular Application of Macrobiomolecules in Anti-Allergy and Anti- Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents